Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 TherapyCOVID-19 치료에 사용되는 항체에 의한 중화로부터 보호할 수 있는 ACE2 독립적 진입 경로에 대한 증거Article Published on 2022-06-282022-09-11 Journal: mBio [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료제, [키워드] ACE2 ACE2 binding analyzed antibody Antibody-mediated neutralization blockade Can cell entry cell line cellular receptor COVID-19 COVID-19 patient COVID-19 therapy E484K Evidence hepatoma host cells Huh-7 Imdevimab Infection Interaction lung cell mechanism Mutation NCI-H1299 neutralization Neutralizing antibodies neutralizing antibody position PROTECT Protein rescued SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants spike Spike protein the SARS-CoV-2 therapy vaccination variants of concern Vero Cell Viral viral entry virus VoC [DOI] 10.1128/mbio.00364-22 PMC 바로가기 [Article Type] Article
[Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2][SARS-CoV-2에 대한 세파란틴의 항바이러스 활성 연구 진행]Article Published on 2022-06-202022-09-11 Journal: Nan fang yi ke da xue xue bao = Journal of Souther [Category] COVID19(2023년), SARS, 치료제, [키워드] alkaloid Anti-SARS-CoV-2 Activity Antiviral antiviral activity Cepharanthine Chinese clinical trial clinical trials concerning COVID-19 COVID-19 therapy English inhibitory effect ISOQUINOLINE leukopenia mechanism member other diseases recent Research research progress. SARS-CoV-2 therapy Traditional Chinese medicine Treatment widespread [DOI] 10.12122/j.issn.1673-4254.2022.06.22 PMC 바로가기 [Article Type] Article
Characterization of the Interaction Between SARS-CoV-2 Membrane Protein (M) and Proliferating Cell Nuclear Antigen (PCNA) as a Potential Therapeutic Target잠재적 치료 표적으로서 SARS-COV-2 막 단백질 (M)과 증식 세포 핵 항원 (PCNA) 사이의 상호 작용의 특성화Article Published on 2022-05-232022-08-31 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘, [키워드] addition association Cell characterization Coronaviridae family COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 therapy cytoplasm DNA DNA damage DNA replication expression function immunofluorescence immunohistochemistry immunoprecipitation in vitro increase in infected with SARS-CoV-2 Interaction ligation Localization lung M protein marker membrane protein nucleus PCNA Potential reduction repair reported responsible SARS-CoV-2 target the Coronaviridae therapy transfected with translocation Transport Verdinexor viral-host interaction virion virus [DOI] 10.3389/fcimb.2022.849017 PMC 바로가기 [Article Type] Article
Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 TherapySARS-CoV-2에서 돌연변이를 유발하는 원동력 이해: 돌연변이 에너지와 COVID-19 치료에서 아르기닌 차단제의 역할Article Published on 2022-05-112022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] 3CLpro accelerated ACE2 ACE2 protein Alpha Amino acid amino acids angiotensin Angiotensin receptor blockers angiotensin type1 receptor Angiotensin-converting enzyme anionic antiviral drug arginine assist association Beta binding biphenyl bisartans blocker blockers candidate drug cleavage site cleavage sites complex complexes Computational approaches conformation conformational contribute COVID-19 COVID-19 therapy Critical Delta delta variant driving drug energetics ENhance equilibrium Evolution of SARS-CoV-2 force furin furin cleavage site Gamma human clinical trials human population hydrolysis hydropathy hydrophilic hydrophobic interaction in silico Infection Interaction interactions interface investigated Lambda molecular Molecular biology molecular dynamic simulations molecular dynamics mutant mutants mutate Mutation omicron Omicron variants pharmacophores polar Protein RBD RBD binding RBD-ACE2 receptor Receptor-binding domain referred to replacement Replication Research residue residues role S-protein salt salt bridges SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 variants SARS-CoV-2 virus sartans Spread suggested target targets tetrazole the RBD the receptor-binding domain the SARS-CoV-2 virus Therapies translation Treatment treatment of COVID-19 Trigger understanding variant variants viral infection virus wild-type virus π-π interaction [DOI] 10.3390/v14051029 PMC 바로가기 [Article Type] Article
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapyCOVID-19 치료를 위한 SARS-CoV-2 변이체를 중화하는 인간 흡입 가능한 항체 단편Article Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration aerosol aerosol therapy animal models anti-COVID-19 antibody antibody antibody fragment caused cell-cell fusion cells coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 pathology COVID-19 therapy Critical delta variant Efficiency epitope Human human single-chain antibody Immune status independent Infection inhalation inhibit Intervention intranasal intranasal administration nebulization neutralize Neutralizing other variant other variants phage display Resilience respiratory SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variant neutralization scFv severe acute respiratory syndrome Coronavirus single-chain variable fragment Spike protein stability subject the SARS-CoV-2 therapy [DOI] 10.1016/j.ymthe.2022.02.013 PMC 바로가기 [Article Type] Article
SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccinationSARS-CoV-2 변이체 C.1.2 및 B.1.621(Mu)은 감염 또는 백신 접종 시 유도된 항체에 의한 중화를 부분적으로 회피합니다.Article Published on 2022-05-032022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 binding Americas antibody antibody cocktail B.1.351 B.1.621 bamlanivimab Beta Beta variant C.1.2 cell line cell lines close monitoring COVID-19 COVID-19 therapy CP: Immunology CP: Microbiology elevated elicited escape evade Health immunology Infection Microbiology Mu Mutation neutralization raised Rapid SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants spike Spike protein Spike proteins Spread therapy vaccination vaccine-induced antibodies vaccine-induced antibody variant variants Viral viral spike protein viral spike proteins [DOI] 10.1016/j.celrep.2022.110754 PMC 바로가기 [Article Type] Article
There is nothing exempt from the peril of mutation – The Omicron spike돌연변이의 위험에서 예외는 없다 - 오미크론 스파이크Review Published on 2022-04-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] ACE2 angiotensin angiotensin-converting enzyme 2 antibody approach approved binding caused Corona Corona virus COVID-19 COVID-19 therapy elevated entry pathway enzyme followed by Health Organization healthcare Healthcare system Interaction kinase inhibitors manuscript mutated Mutation omicron Omicron variant pandemic protease inhibitors RBD Receptor binding domain referred to researcher responsible risk spike Spike protein target the spike protein therapy Transmission Treatment Vaccine variant variant of concern verge Virus Disease VoC WHO World Health Organization [DOI] 10.1016/j.biopha.2022.112756 PMC 바로가기 [Article Type] Review
The vital role of animal, marine, and microbial natural products against COVID-19Covid-19에 대한 동물, 해양 및 미생물 천연 제품의 중요한 역할Review Published on 2022-03-022022-09-10 Journal: Pharmaceutical Biology [Category] 신약개발, 치료제, [키워드] 3CLpro animal Anti-inflammatory Antiviral approach Bromelain carrageenan clinical trial clinical trials Combination combination treatment Context COVID-19 COVID-19 therapy COVID19 database derivative Direct Drug development Effect Efficacy evaluated flavonoids hACE2 highlighting host proteins immunomodulatory properties in silico inhibitory less management mechanism microbial microbial products microorganisms MOST nasal Nasal spray NF-κB objective omega-3 omega-3 supplementation organism outbreak pandemic Pathogenesis peptide peptides pharmacological plants PLPro Prevent profile quercetin raw data researcher Result SARS-CoV-2 SARS-CoV-2coronavirus Science Science Direct searched synergistic synergistic effects tannins target tested therapy these compound these compounds Treatment Viral viral entry Vitamin C Zinc [DOI] 10.1080/13880209.2022.2039215 PMC 바로가기 [Article Type] Review
Advances Toward COVID-19 Therapies Special IssueCOVID-19 치료 특별호를 향한 발전Editorial Published on 2022-02-242022-09-11 Journal: Journal of medicinal chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] advance COVID-19 therapy issue [DOI] 10.1021/acs.jmedchem.2c00178 PMC 바로가기 [Article Type] Editorial
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 TherapiesPharmacology Published on 2022-02-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ABCB1 ABCC2 accelerate Administered anti-SARS-CoV-2 APOA5 association CES1 clinical effectiveness clinical settings Compound Computational study conditions coronavirus disease COVID-19 COVID-19 patient COVID-19 therapy CYP2B6 CYP2C19 CYP2C9 described docking drug Drug-drug interactions drug-herb interactions drug–drug interaction drugs effective Evidence FCGR3A feasible HLA improvement in silico information Interaction Intervention Medicine molecular docking multifactorial non-steroidal anti-inflammatory drug pandemic pathogenesis and severity pharmacogenetic pharmacogenetics pharmacokinetic Precision precision medicine Repurposed drug Repurposed drugs SARS-COV-2 infection SLC28A2 SLCO1B1 SLCO1B3 target therapy these compound UGT1A1 unlikely VKORC1 [DOI] 10.3389/fphar.2022.835136 PMC 바로가기 [Article Type] Pharmacology